Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2011

Open Access 01-11-2011 | Original Article

Gastric Juice Prostaglandins and Peptide Growth Factors as Potential Markers of Chronic Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer: Their Potential Clinical Implications Based on this Pilot Study

Authors: Ajoy Dias, Cesar Garcia, Marek Majewski, Grzegorz Wallner, Richard W. McCallum, Cezary Poplawski, Jerzy Sarosiek

Published in: Digestive Diseases and Sciences | Issue 11/2011

Login to get access

Abstract

Background

Gastric secretion can provide valuable information especially when Helicobacter pylori (Hp) infection results in chronic atrophic gastritis (CAG) and intestinal metaplasia (IM) preceding adenocarcinoma (AdCa).

Aims

Looking for a potential biomarker of malignant transformation in the setting of chronic inflammation we studied the levels of prostaglandin E2 (PGE2), as well as peptide growth factors [epidermal growth factor (EGF) and transforming growth factor α (TGFα)], harbingers of injury and repair, in gastric juice aspirated at endoscopy from patients with CAG, CAG/IM, AdCa, and controls.

Methods

The PGE2, EGF and TGFα concentrations in the gastric juice were measured using radioimmunoassays (RIAs).

Results

In patients with AdCa gastric juice PGE2 increased fivefold versus controls (P < 0.01) and almost threefold versus patients with CAG (P < 0.05). The EGF levels in patients with AdCa were fourfold higher versus controls (P < 0.001) and almost threefold higher versus CAG (P < 0.05). In patients with CAG/IM the EGF levels were also almost 3 times higher versus controls. The TGFα levels in patients with AdCa were half the value of controls and CAG (P < 0.05). In patients with CAG/IM the levels were as low as 1/5 of controls or CAG (P < 0.05).

Conclusions

Testing the gastric juice for PGE2, EGF, and TGFα in patients with endoscopy and biopsy proven CAG, may be helpful in follow up of patients who may potentially progress to IM and ultimately AdCa. This could be considered as an adjunct to histologic assessment especially that even the best surveillance biopsy specimen regimens are inherited with sampling errors.
Literature
1.
go back to reference Goldberg HI, Dodds WJ, Gee S, et al. Role of acid and pepsin in acute experimental esophagitis. Gastroenterology. 1969;56:223–230.PubMed Goldberg HI, Dodds WJ, Gee S, et al. Role of acid and pepsin in acute experimental esophagitis. Gastroenterology. 1969;56:223–230.PubMed
2.
go back to reference Richter JE. The symptom index: correlation of acid reflux with symptoms. In: Richter JE, ed. Ambulatory esophageal pH monitoring. New York: Igaku-Shoin; 1991:93–100. Richter JE. The symptom index: correlation of acid reflux with symptoms. In: Richter JE, ed. Ambulatory esophageal pH monitoring. New York: Igaku-Shoin; 1991:93–100.
3.
go back to reference Slomiany BL, Sarosiek J, Slomiany A. Gastric mucus and the mucosal barrier. Dig Dis. 1987;5:125–145.PubMedCrossRef Slomiany BL, Sarosiek J, Slomiany A. Gastric mucus and the mucosal barrier. Dig Dis. 1987;5:125–145.PubMedCrossRef
4.
go back to reference Sarosiek J, Feng T, McCallum RW. The interrelationship between salivary epidermal growth factor and the functional integrity of the esophageal mucosal barrier in the rat. Am J Med Sci. 1991;302:359–363.PubMedCrossRef Sarosiek J, Feng T, McCallum RW. The interrelationship between salivary epidermal growth factor and the functional integrity of the esophageal mucosal barrier in the rat. Am J Med Sci. 1991;302:359–363.PubMedCrossRef
5.
go back to reference Sarosiek J, Bilski J, Murty VLN, et al. Role of salivary epidermal growth factor in the maintenance of physicochemical characteristics of oral and gastric mucus coat. Biochem Biophys Res Commun. 1988;152:1421–1427.PubMedCrossRef Sarosiek J, Bilski J, Murty VLN, et al. Role of salivary epidermal growth factor in the maintenance of physicochemical characteristics of oral and gastric mucus coat. Biochem Biophys Res Commun. 1988;152:1421–1427.PubMedCrossRef
6.
go back to reference Sarosiek J, McCallum RW. The evolving appreciation of the role of esophageal mucosal protection in the pathophysiology of gastroesophageal reflux disease. J Pract Gastroenterol. 1994;18:20J–20Q. Sarosiek J, McCallum RW. The evolving appreciation of the role of esophageal mucosal protection in the pathophysiology of gastroesophageal reflux disease. J Pract Gastroenterol. 1994;18:20J–20Q.
7.
go back to reference Rourk RM, Namiot Z, Sarosiek J, et al. Diminished content of esophageal epidermal growth factor in patients with reflux esophagitis. Am J Gastroenterol. 1994;89:1177–1184.PubMed Rourk RM, Namiot Z, Sarosiek J, et al. Diminished content of esophageal epidermal growth factor in patients with reflux esophagitis. Am J Gastroenterol. 1994;89:1177–1184.PubMed
8.
go back to reference Rourk RM, Namiot Z, Sarosiek J, et al. Impairment of salivary epidermal growth factor secretory response to esophageal mechanical and chemical stimulation in patients with reflux esophagitis. Am J Gastroenterol. 1994;89:237–244.PubMed Rourk RM, Namiot Z, Sarosiek J, et al. Impairment of salivary epidermal growth factor secretory response to esophageal mechanical and chemical stimulation in patients with reflux esophagitis. Am J Gastroenterol. 1994;89:237–244.PubMed
9.
go back to reference Sarosiek J, Jensen TJ, Maton PN, et al. Gastric salivary epidermal growth factor in patients with Zollinger-Ellison syndrome: its protective potential. Am J Gastroenterol. 2000;95:1158–1165.PubMedCrossRef Sarosiek J, Jensen TJ, Maton PN, et al. Gastric salivary epidermal growth factor in patients with Zollinger-Ellison syndrome: its protective potential. Am J Gastroenterol. 2000;95:1158–1165.PubMedCrossRef
10.
go back to reference Kelly RW, Graham BJM, O’Sullivan MJ. Measurement of PGE2 as the methyl oximate by the radioimmunoassay using a novel iodinated label. Prostagland Leukotrienes Essential Fatty Acids. 1989;89:588–594. Kelly RW, Graham BJM, O’Sullivan MJ. Measurement of PGE2 as the methyl oximate by the radioimmunoassay using a novel iodinated label. Prostagland Leukotrienes Essential Fatty Acids. 1989;89:588–594.
11.
go back to reference Sarosiek J, Yu Z, Namiot Z, et al. Impact of acid and pepsin on human esophageal prostaglandins. Am J Gastroenterol. 1994;89:588–594.PubMed Sarosiek J, Yu Z, Namiot Z, et al. Impact of acid and pepsin on human esophageal prostaglandins. Am J Gastroenterol. 1994;89:588–594.PubMed
12.
go back to reference Marcinkiewicz M, Sarosiek J, Edmunds MC, et al. Monophasic luminal release of prostaglandin E2 in patients with reflux esophagitis under the impact of acid and acid/pepsin solutions: its potential pathogenetic significance. J Clin Gastroenterol. 1995;21:268–274.PubMedCrossRef Marcinkiewicz M, Sarosiek J, Edmunds MC, et al. Monophasic luminal release of prostaglandin E2 in patients with reflux esophagitis under the impact of acid and acid/pepsin solutions: its potential pathogenetic significance. J Clin Gastroenterol. 1995;21:268–274.PubMedCrossRef
13.
go back to reference Kim YJ, Chung JW, Lee SJ, et al. Progression from chronic atrophic gastritis to gastric cancer; tangle, toggle, tackle with Korea red ginseng. J Clin Biochem Nutr. 2010;46:195–204.PubMedCrossRef Kim YJ, Chung JW, Lee SJ, et al. Progression from chronic atrophic gastritis to gastric cancer; tangle, toggle, tackle with Korea red ginseng. J Clin Biochem Nutr. 2010;46:195–204.PubMedCrossRef
14.
go back to reference Oshima H, Tazawa H, Sylla BS, Sawa T. Prevention of human cancer by modulation of chronic inflammatory process. Mutat Res. 2005;591:110–122.CrossRef Oshima H, Tazawa H, Sylla BS, Sawa T. Prevention of human cancer by modulation of chronic inflammatory process. Mutat Res. 2005;591:110–122.CrossRef
16.
go back to reference Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–1131.PubMedCrossRef Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–1131.PubMedCrossRef
17.
18.
go back to reference Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther. 1999;13:851–856.PubMedCrossRef Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther. 1999;13:851–856.PubMedCrossRef
19.
go back to reference Fox JG, Sheppard BJ, Dangler CA, et al. Germ-line p53-targeted disruption inhibits Helicobacter-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses. Cancer Res. 2002;62:696–702.PubMed Fox JG, Sheppard BJ, Dangler CA, et al. Germ-line p53-targeted disruption inhibits Helicobacter-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses. Cancer Res. 2002;62:696–702.PubMed
20.
go back to reference Rieder G, Merchant JL, Haas R. Helicobacter pylori cag-type IV secretion system facilitates corpus colonization to induce precancerous conditions in Mongolian gerbils. Gastroenterology. 2005;128:1229–1242.PubMedCrossRef Rieder G, Merchant JL, Haas R. Helicobacter pylori cag-type IV secretion system facilitates corpus colonization to induce precancerous conditions in Mongolian gerbils. Gastroenterology. 2005;128:1229–1242.PubMedCrossRef
21.
22.
go back to reference Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56:387–437.PubMedCrossRef Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56:387–437.PubMedCrossRef
23.
go back to reference Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79:1193–1226.PubMed Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79:1193–1226.PubMed
24.
go back to reference Potter JD, Ulrich CM. COX-2 and gastric cancer: more on inflammation and neoplasia. Gastroenterology. 2006;130:2198–2200.PubMedCrossRef Potter JD, Ulrich CM. COX-2 and gastric cancer: more on inflammation and neoplasia. Gastroenterology. 2006;130:2198–2200.PubMedCrossRef
25.
go back to reference Liu F, Pan K, Zhang X, et al. Genetic variants in cyclooxygenase-2: expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology. 2006;130:1975–1984.PubMedCrossRef Liu F, Pan K, Zhang X, et al. Genetic variants in cyclooxygenase-2: expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology. 2006;130:1975–1984.PubMedCrossRef
26.
go back to reference Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 2006;6:130–140.PubMedCrossRef Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 2006;6:130–140.PubMedCrossRef
27.
go back to reference Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48:4399–4404.PubMed Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48:4399–4404.PubMed
28.
go back to reference Wang WH, Huang JQ, Zheng GF, et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2003;95:1784–1791.PubMed Wang WH, Huang JQ, Zheng GF, et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2003;95:1784–1791.PubMed
29.
go back to reference Wang D, DuBois RN. Inflammatory mediators and nuclear receptor signaling in colorectal cancer. Cell Cycle. 2007;6:682–685.PubMedCrossRef Wang D, DuBois RN. Inflammatory mediators and nuclear receptor signaling in colorectal cancer. Cell Cycle. 2007;6:682–685.PubMedCrossRef
30.
go back to reference Cha YI, Dubois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med. 2007;58:239–252.PubMedCrossRef Cha YI, Dubois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med. 2007;58:239–252.PubMedCrossRef
31.
go back to reference Pockaj BA, Basu GD, Pathangey LB, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol. 2004;11:328–339.PubMedCrossRef Pockaj BA, Basu GD, Pathangey LB, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol. 2004;11:328–339.PubMedCrossRef
32.
go back to reference Jang TJ. Expression of proteins related to prostaglandin E2 biosynthesis is increased in human gastric cancer, during gastric carcinogenesis. Virchow’s Arch. 2004;445:564–571.CrossRef Jang TJ. Expression of proteins related to prostaglandin E2 biosynthesis is increased in human gastric cancer, during gastric carcinogenesis. Virchow’s Arch. 2004;445:564–571.CrossRef
33.
go back to reference Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122:518–523.PubMed Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122:518–523.PubMed
34.
go back to reference Bennett A, Civier A, Hensby CN, Melhuish PB, Stamford IF. Measurement of arachinodate and its metabolites extracted from human normal and malignant gastrointestinal tissues. Gut. 1987;28:315–318.PubMedCrossRef Bennett A, Civier A, Hensby CN, Melhuish PB, Stamford IF. Measurement of arachinodate and its metabolites extracted from human normal and malignant gastrointestinal tissues. Gut. 1987;28:315–318.PubMedCrossRef
35.
go back to reference McLemore TL, Hubbard WC, Litterst CL, et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 1998;58:3140–3147. McLemore TL, Hubbard WC, Litterst CL, et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 1998;58:3140–3147.
36.
go back to reference Ding Y-B, Shi R-H, Tong J-D, et al. PGE2 up-regulates vascular endothelial growth factor expression in MKN28 Gastric cancer cells via epidermal growth factor receptor signalling system. Exp Oncol. 2005;27:108–113.PubMed Ding Y-B, Shi R-H, Tong J-D, et al. PGE2 up-regulates vascular endothelial growth factor expression in MKN28 Gastric cancer cells via epidermal growth factor receptor signalling system. Exp Oncol. 2005;27:108–113.PubMed
37.
go back to reference Nakajima T, Konda Y, Izumi Y, et al. Gastrin stimulates the growth of gastric pit cell precursors by inducing its own receptors. Am J Physiol Gastrointest Liver Physiol. 2002;282:G359–G366.PubMed Nakajima T, Konda Y, Izumi Y, et al. Gastrin stimulates the growth of gastric pit cell precursors by inducing its own receptors. Am J Physiol Gastrointest Liver Physiol. 2002;282:G359–G366.PubMed
38.
go back to reference Fu QL, Yang MF, Li ZJ, et al. Prostaglandin E (PGE), gastric carcinoma. Zhonghua Zhong Liu Za Zhi. 1986;8:345–348.PubMed Fu QL, Yang MF, Li ZJ, et al. Prostaglandin E (PGE), gastric carcinoma. Zhonghua Zhong Liu Za Zhi. 1986;8:345–348.PubMed
39.
go back to reference Kushlinkskiĭ NE, Klimenkov AA, Abdraimov SB, Rommenberg VI, Liakina LT. Prostaglandins E in malignant stomach neoplasms. Vopr Onkol. 1994;40:171–176.PubMed Kushlinkskiĭ NE, Klimenkov AA, Abdraimov SB, Rommenberg VI, Liakina LT. Prostaglandins E in malignant stomach neoplasms. Vopr Onkol. 1994;40:171–176.PubMed
40.
go back to reference Playford RJ, Wright NA, Marchbank T. Endogenous peptides and peptide therapy in gut defense and repair. Drug News Perspect. 2000;13:330.PubMed Playford RJ, Wright NA, Marchbank T. Endogenous peptides and peptide therapy in gut defense and repair. Drug News Perspect. 2000;13:330.PubMed
41.
go back to reference Wright NA, Pike C, Elia G. Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells. Nature. 1990;343:82–85.PubMedCrossRef Wright NA, Pike C, Elia G. Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells. Nature. 1990;343:82–85.PubMedCrossRef
42.
go back to reference Playford PJ, Harby A, Gschmeissner S, Peiffer LP, McGarrity T, Wright NA. The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical surface of the enterocytes in the human gastrointestinal tract. Gut. 1996;38:303–305.PubMedCrossRef Playford PJ, Harby A, Gschmeissner S, Peiffer LP, McGarrity T, Wright NA. The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical surface of the enterocytes in the human gastrointestinal tract. Gut. 1996;38:303–305.PubMedCrossRef
43.
go back to reference Sarosiek J, Feng T, McCallum RW. The interrelationship between salivary epidermal growth factor and the functional integrity of the esophageal mucosal barrier in the rat. Am J Med Sci. 1991;302:359–363.PubMedCrossRef Sarosiek J, Feng T, McCallum RW. The interrelationship between salivary epidermal growth factor and the functional integrity of the esophageal mucosal barrier in the rat. Am J Med Sci. 1991;302:359–363.PubMedCrossRef
45.
go back to reference Barnard JA, Beauchamp RD, Russell WE, Dubois RN, Coffey RJ. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology. 1995;108:564–580.PubMedCrossRef Barnard JA, Beauchamp RD, Russell WE, Dubois RN, Coffey RJ. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology. 1995;108:564–580.PubMedCrossRef
46.
go back to reference Ciacci C, Lind SE, Podolsky DK. Transforming growth factor beta regulation of migration in wounded rat intestinal epithelial monolayers. Gastroenterology. 1993;105:93–101.PubMed Ciacci C, Lind SE, Podolsky DK. Transforming growth factor beta regulation of migration in wounded rat intestinal epithelial monolayers. Gastroenterology. 1993;105:93–101.PubMed
47.
go back to reference Konturek JW, Bielanski W, Konturek SJ, Bogdal J, Olesky J. Distribution and release of epidermal growth factor in man. Gut. 1989;30:1194–1200.PubMedCrossRef Konturek JW, Bielanski W, Konturek SJ, Bogdal J, Olesky J. Distribution and release of epidermal growth factor in man. Gut. 1989;30:1194–1200.PubMedCrossRef
48.
go back to reference Konturek SJ, Brzozowski T, Majka J, Dembinski A, Slomiany A, Slomiany BL. Transforming growth factor alpha and epidermal growth factor in protection and healing of gastric mucosal injury. Scand J Gastroenterol. 1992;27:649–655.PubMedCrossRef Konturek SJ, Brzozowski T, Majka J, Dembinski A, Slomiany A, Slomiany BL. Transforming growth factor alpha and epidermal growth factor in protection and healing of gastric mucosal injury. Scand J Gastroenterol. 1992;27:649–655.PubMedCrossRef
49.
go back to reference Skov Olsen P, Poulsen SS, Therkelsen K, Nex E. Effect of sialoadenectomy and synthetic human urogastrone on healing of chronic duodenal ulcers in rats. Gut. 1986;27:1443–1449.CrossRef Skov Olsen P, Poulsen SS, Therkelsen K, Nex E. Effect of sialoadenectomy and synthetic human urogastrone on healing of chronic duodenal ulcers in rats. Gut. 1986;27:1443–1449.CrossRef
50.
go back to reference Konturek SJ, Dembinski A, Warzecha Z, Brzozowski T, Gregory H. Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats. Gastroenterology. 1988;94:1300–1307.PubMed Konturek SJ, Dembinski A, Warzecha Z, Brzozowski T, Gregory H. Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats. Gastroenterology. 1988;94:1300–1307.PubMed
51.
go back to reference Konturek PC, Bielanski W, Konturek SJ, Hahn EG. Gastric mucosal expression and luminal release of growth factors in gastric carcinoma and duodenal ulcer patients before and after eradication of helicobacter pylori. J Physiol Pharmacol. 1997;48:375–382.PubMed Konturek PC, Bielanski W, Konturek SJ, Hahn EG. Gastric mucosal expression and luminal release of growth factors in gastric carcinoma and duodenal ulcer patients before and after eradication of helicobacter pylori. J Physiol Pharmacol. 1997;48:375–382.PubMed
Metadata
Title
Gastric Juice Prostaglandins and Peptide Growth Factors as Potential Markers of Chronic Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer: Their Potential Clinical Implications Based on this Pilot Study
Authors
Ajoy Dias
Cesar Garcia
Marek Majewski
Grzegorz Wallner
Richard W. McCallum
Cezary Poplawski
Jerzy Sarosiek
Publication date
01-11-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1758-z

Other articles of this Issue 11/2011

Digestive Diseases and Sciences 11/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine